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www.cdatm.orgAbstractObjective: To evaluate the efficacy and short term prognosis of Tirofiban in different treatment duration in patients with acute ST
segment elevation myocardial infarction (STEMI) and percutaneous coronary intervention (PCI) combined with intracoronary
injection.
Methods: A total of 125 patients with acute STEMI were enrolled in this study. They were randomly divided into two
groups: control group (n ¼ 61) and Tirofiban group (n ¼ 64). The Tirofiban was used by intracoronary and intravenous
administration in Tirofiban group which was randomly divided into three sub-groups according to the duration of Tirofiban by
persistent intravenous injection for 12 hours, 24 hours or 36 hours. Thrombolysis in myocardial infarction flow and
myocardial perfusion grades were recorded immediately after PCI. The adverse cardiac events and cardiac death within 180
days of PCI, and the adverse effects (hemorrhage and thrombocytopenia) were compared between the two groups and within
Tirofiban sub-groups.
Results: Grade 3 in myocardial perfusion was significantly better in Tirofiban group than control group (85.94% vs. 72.13%,
P ¼ 0.03) after PCI. There was one cardiac death in control group in 180 days after PCI. The adverse cardiac event rates between
two groups was significant difference (16 patients in control group and only 8 in Tirofiban group, P ¼ 0.047). There was no
significant difference in incidence of hemorrhage complications and platelet counts between two groups. Nevertheless, hemorrhage
complications in the 12- and 24-hour subgroups were less than 36-hour subgroup (P ¼ 0.01).* Corresponding author. Tel.: þ86 311 85990692; fax: þ86 311 85990501.
E-mail address: jzg6301@163.com (Z.-G. Ji).
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82 Z.-G. Ji et al. / Chronic Diseases and Translational Medicine 1 (2015) 81e88Conclusions: Intravenous Tirofiban treatment reduced the adverse cardiac events and improved short term prognosis without
increasing the adverse reactions of the drugs in patients undergoing PCI. The less rate of hemorrhage complication can be achieved
in short-duration of Tirofiban by intravenous injection after PCI.
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Percutaneous coronary intervention (PCI) is an
important and the effectivest method used to revascu-
larize the target vessel and to save the life of patients
with ST-segment elevation myocardial infarction
(STEMI).1,2 Clinical randomized trials and observa-
tional studies have demonstrated that adjunctive infu-
sion of glycoprotein (GP) IIb/IIIa inhibitors
(intravenous and intracoronary bolus administration) is
associated with improved clinical outcomes and further
reduced mortality of the patients with STEMI.3e5
Standard Tirofiban regimen consists of an intravenous
(IV) bolus followed by an intracoronary (IC) bolus
administration and 12e72 h IV infusion.6,7 However,
whether longer duration of Tirofiban IV infusion would
result in improved clinical outcomes and decrease the
incidence of complications or not is unknown. The aim
of this study was to compare the efficacy and prognosis
of intracoronary bolus followed by different duration of
IV maintenance infusion of Tirofiban with respect to
improvement in outcomes and complications after PCI.
Methods
Patient selection
125 patients with STEMI and age<80 years admitted
to The First Hospital of Hebei Medical University and
The Third Hospital of Shijiazhuang City from April
2010 to February 2012 were enrolled in this study. In-
clusion criteria: ST-segment elevation of two adjacent
leads >0.1 mV, presenting within 12 hours of symptom
onset and admission. All the patients underwent primary
PCI by the right radial approach with Thrombolysis In
Myocardial Infarction (TIMI) flow grade in the infarc-
tion related artery (IRA) which was described as grade
0 or 1. Only IRA underwent intervention. Patients who
had any one of the following conditions were excluded
from the study: (1) cardiac function class III and IV
(Killip classification); (2) definite resistance or allergyto anti-platelet drugs; (3) severe hypertension (blood
pressure >180/110 mmHg, 1 mmHg ¼ 0.133 kPa); (4)
previous history of cerebral hemorrhage or cerebral
infarction in the last six months or visceral hemorrhage
in recent onemonth; (5) blood coagulation disorders and
platelet count <100  109/L; (6) serum creatinine
>177 mmol/L, hemodialysis patients; (7) history of
heparin-caused thrombocytopenia and heparin allergy;
(8) left main artery stenosis>50% or severe triple vessel
lesion; (9) unable to complete the procedure by radial
artery and not willing to participate in the study; (10)
Non-STEMI or undergoing PCI or coronary artery
bypass grafting procedure in six-month.
After initial evaluation and coronary artery angi-
ography (CAG), a total of 125 eligible patients were
randomly (simple randomization) divided into two
groups: control group (intracoronary saline, n ¼ 61)
and study group (intracoronary Tirofiban, n ¼ 64) with
maintenance infusion for 12 h, 24 h or 36 h. All the
patients gave a written informed consent and institu-
tional ethics committee approved the study.
Medication scheme
All the patients received pre-treated with aspirin
(300 mg) and clopidogrel (600 mg) immediately before
CAG with heparin 3000 IU via the radial artery. After
the diagnostic CAG was performed, an initial intrave-
nous bolus dose of 100 IU/kg and a maximal dose of
10000 IU was given. The maintenance dosage was
adjusted according to the values of activated clotting
time (ACT) which were closely monitored during PCI
for a total of 250e300 seconds. Primary PCI was
performed according to routine procedures. Tirofiban
bolus (study groups) or saline (control group) was
administered after successful passage of guidewire
with/without predilatation by a balloon immediately
after the first restoration of antegrade flow. The patients
in Tirofiban group received a bolus dose of Tirofiban
10 mg/kg via IC through the guiding catheter in the
IRA over a period of 30 s, followed by a 12 hours (12 h
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subgroup) of IV infusion at 0.15 mg$kg1$min1. As
the final step, stenting (Everolimus Eluting Coronary
Stent) was performed. Heparin with 500e700 U/h was
given for 12 h after PCI by IV according to ACT. All
the patients routinely took aspirin 100 mg, clopidogrel
75 mg, beta-blocker, statin and an angiotensin-
converting enzyme inhibitor, unless contraindicated.
A low-molecular-weight heparin, enoxaparine, was
given for 3e5 days after the procedure unless
contraindicated.
Electrocardiogram (ECG) analysis
A 12-lead ECG was acquired before PCI and 60
minutes after PCI. ST-segment elevation was measured
60 ms from the J-point. The sum of ST-segment ele-
vations (sigmaSTE), ST resolution (STR) and the rate
of STR (STR%) was assessed by comparing the ST-
segment elevation in the infarct-related area on the
ECG before PCI with the post-interventional ECG with
the minimum elevation.8 All ECG recordings were
analyzed by an experienced physician.
Angiographic analysis
The following were recorded from the offline
angiographic analysis of the whole procedure. TIMI
flow grades,9 TIMI myocardial perfusion (TMP) grade
in the culprit vessel which was described as grade
0 ¼Failure of dye to enter the microvasculature,
1 ¼Dye slowly enters but fails to exit the microvas-
culature, 2 ¼ Delayed entry and exit of dye from the
microvasculature, and 3 ¼ Normal entry and exit of
dye from the microvasculature.10 All the visual as-
sessments were performed offline by an experienced
blinded interventionalist.
Left ventricular function
Echocardiography was performed by two cardiol-
ogy specialists using IE33 instruments (Philips Medi-
cal Systems, Milwaukee, WI, USA), with a 2.5-MHz
transducer. The left ventricular ejection fraction
(LVEF) was assessed using the modified biplane
Simpson's method after the seventh day and thirtieth
day of PCI.
Clinical end-points
Clinical follow-up of each patient was obtained
from hospital records and interviews.Adverse cardiac events and cardiac death
Adverse cardiac events and cardiac death were
defined as acute myocardial infarction, repeat revas-
cularization, cardiac death, angina pectoris, heart fail-
ure and malignant arrhythmias which occurred
duration of hospitalization or within 6 months after
primary PCI.
Hemorrhage events and thrombocytopenia
Bleeding events from the beginning of Tirofiban
administration to the discharge of patients were cate-
gorized by the change in hemoglobin using the TIMI
criteria.11 Major hemorrhage required a decrease in
hemoglobin of more than 50 g/L or intracranial or
pericardial bleeding. Minor hemorrhage consisted of a
decrease in hemoglobin between more than 30 g/L and
50 g/L with a documented site or between more than
40 g/L and 50 g/L without an identified site or hema-
turia, hematochezia, or hematemesis. Insignificant
hemorrhage complications which were defined as
blood loss insufficient to meet major or minor criteria
were also included in the minor bleeding. Thrombo-
cytopenia is defined as mild when the platelet count is
below 100  109/L, severe when it falls below
50  109/L, and profound when it is below 20  109/L.
Statistical analysis
STATAversion 12.0 (STATA Corp., College Station,
TX, USA) was used for all statistical analyses.
Continuous data were presented as mean
values ± standard deviation (SD) or as counts or pro-
portions (%). Categorical data were compared using
the c2 test or Fisher's exact test when expected cell
values were less than 5. Continuous data were
compared using the t test or one-way analysis of
variance (ANOVA) method and differences between
groups were compared with Scheffe test. A survival
analysis (KaplaneMeier method) was applied to
examine the adverse cardiac events during 180-day of
PCI and bleeding events after PCI. P <0.05 was
considered statistically significant.
Results
Clinical characteristics
There were 125 patients (81 male, 44 female)
enrolled into the study. Baseline characteristics were
well balanced between the control group (61 patients)
and Tirofiban group (64 patients, Table 1). The ages
varied from 38 to 78 (58.70 ± 9.26) years. There were
Table 1
Baseline characteristics.
Items Control (n ¼ 61) Study (n ¼ 64) P value
Age (year) 59.05 ± 10.09 58.36 ± 8.47 0.68
Male (%) 43 38 0.19
Risk factors, No.
Current smoking 28 33 0.53
Hypertension 23 39 0.88
Hypercholesterolaemia 46 41 0.17
Diabetes 17 16 0.72
Prior myocardial infarction 8 7 0.71
Time from symptom-onset to arrival PCI centre (min) 116.07 ± 65.58 119.84 ± 98.03 0.72
Systolic pressure (mmHg) 118.31 ± 22.68 122.66 ± 20.57 0.26
Diastolic pressure (mmHg) 70.41 ± 12.05 73.13 ± 14.02 0.25
Heart rate (beats/min) 74.41 ± 12.05 71.39 ± 16.45 0.33
Characteristics of IRA
Single-vessel disease, n 46 48 0.96
Stent diameter (mm) 3.14 ± 0.39 3.14 ± 0.41 0.94
No. of stent placement 1.07 ± 0.25 1.06 ± 0.24 0.61
Length of stent (mm) 17.84 ± 7.43 17.19 ± 7.78 0.63
IRA 0.19
LAD 19 30 0.07
LCX 12 9 0.40
RCA 30 25 0.26
PCI: percutaneous coronary intervention; RCA: right coronary artery; LAD: left anterior descending coronary artery; LCX: left circumflex coronary
artery; IRA: infarct-related artery.
Table 2
Angiographic data during percutaneous coronary intervention (PCI).
Items Control group
n (%)
Study group
n (%)
P value
TIMI 0 or 1 at baseline 61(100) 64(100) >0.05
TIMI 3 after PCI 55(90.16) 60(93.75) >0.05
TMP 0 at baseline 61(100) 64(100) >0.05
TMP 3 after PCI 44(72.13) 55(85.94) 0.03
TIMI: thrombolysis in myocardial infarction flow grade; TMP: TIMI
myocardial perfusion grade; PCI: percutaneous coronary intervention.
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12 h, 22 patients for 24 h and 21 patients for 36 h in the
Tirofiban group.
Coronary angiography
Baseline TIMI flow was grade 0 or 1 and TMP was
grade 0 in all patients (control group and TirofibanTable 3
LVEF and ST-segment changes between control group and Tirofiban group
Items Control group Study group
12 h
LVEF (%) at 7 days 50.75 ± 5.65 50.52 ± 5.75
LVEF (%) at 30 days 52.31 ± 5.43 52.81 ± 5.17
SigmaSTE (mV) before PCI 9.52 ± 3.58 9.57 ± 5.36
SigmaSTE (mV) after PCI 4.62 ± 3.45 2.86 ± 2.29
STR (%) 51.95 ± 28.09 70.54 ± 19.66
P1 ¼ P-value between control group and study group, P2 ¼ P-value in Tirgroup) before the PCI. Final TIMI 3 flow after PCI was
not significantly different in control group and study
group. TMP grade 3 were different in the study group
compared to the control group after PCI (Table 2).
There was no significant difference in TIMI flow
(P ¼ 0.75, c2 ¼ 0.57) and TMP grade (P ¼ 0.88,
c2 ¼ 0.26) among 3 sub-groups in the study group.
Left ventricular function
LVEF (%) after 7 days (50.75 ± 5.65 vs.
50.94 ± 4.79, P ¼ 0.84, t ¼ 0.20) and 30 days
(52.31 ± 5.43 vs. 52.95 ± 4.41, P ¼ 0.47, t ¼ 0.73) of
PCI was a similar between control group and Tirofiban
group (Table 3). However, there was significant dif-
ference in the changes of LVEF between 7 days and 30
days after PCI in control (P ¼ 0.01, t ¼ 4.26) or
Tirofiban group (P ¼ 0.01, t ¼ 6.52). There were nos.
P1 P2
24 h 36 h
50.18 ± 4.57 52.14 ± 3.89 >0.05 >0.05
52.23 ± 4.00 53.86 ± 4.04 >0.05 >0.05
9.50 ± 4.79 9.57 ± 5.01 >0.05 >0.05
2.59 ± 2.06 2.86 ± 2.29 >0.05 >0.05
72.31 ± 22.67 72.50 ± 13.31 <0.01 >0.05
ofiban groups.
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ST-segment changes in ECG
The sum of ST-segment elevations (sigmaSTE) and
STR% was shown in Table 3. The rate of complete
STR was considerably higher in Tirofiban group than
control group (P <0.01). However, there was no sig-
nificant difference in tirofian groups.
Cardiac adverse events
Total cardiac adverse event were 16 patients in the
control group vs. 8 patients in Tirofiban group at six
months. The individual components of the events in
patients were shown as follows in control group vs.
Tirofiban group: death e 1 vs. 0; recurrent angina pec-
torise 8 vs. 3; recurrent myocardial infarctione 4 vs. 1;
heart failuree 3 vs. 4. However, as shown in Fig. 1, there
was significant difference in free-event survive rate be-
tween the 2 groups at six months after PCI by survive
analysis (P ¼ 0.047, c2 ¼ 3.93). The cardiac adverse
event rate in the Tirofiban group was lower than in
control group. There was no significant difference in the
sub-groups of Tirofiban group (P ¼ 0.87, c2 ¼ 0.29).
Hemorrhage complications and platelet reduction
Minor hemorrhage was developed in 22 patients
(control: 9 vs. Tirofiban: 13). No major hemorrhageFig. 1. KaplaneMeier estimates of event-free rate during the first 180 d
coronary intervention, CI: confidence interval (95%).was observed in control group. 3 patients developed
major hemorrhage in Tirofiban group (gastrointestinal
hemorrhage). The difference in hemorrhage compli-
cations was not significant between two groups (c2 ¼
1.80, P ¼ 0.18). It showed KaplaneMeier curves for
hemorrhage survive rate during the first 7 days for
patients in two groups in Fig. 2. It showed the curves
for free-hemorrhage survive rate among study sub-
groups during the first 7 days (c2 ¼ 8.66, P ¼ 0.01)
in Fig. 3. More hemorrhage complication was devel-
oped in 36-hour group than other two sub-groups.
The changes in the platelet count were not signifi-
cant in no matter whether control group and Tirofiban
group or subgroups.
Discussion
This study demonstrates that intracoronary admin-
istration of high dose bolus of Tirofiban with mainte-
nance infusion for short duration (only for 12 h) leads
to improve myocardial reperfusion and clinical out-
comes at 180 days, and does not increase hemorrhage
events in STEMI patients undergoing PCI. It may
suggest that the more hemorrhage events relate to the
dosage and administration duration of the GP in-
hibitors. The beneficial effects of intravenous GP IIb/
IIIa antagonists may be somewhat offset by their
associated increased risk of minor hemorrhage though
that the agent do not have a significant impact on major
hemorrhage except for heparin infusion was continued
after the procedure in which major hemorrhage wasays between control group and Tirofiban group. PCI: percutaneous
Fig. 3. KaplaneMeier estimates of bleeding event-free rate during the first 7 days within Tirofiban sub-groups. PCI: percutaneous coronary
intervention, CI: confidence interval (95%).
Fig. 2. KaplaneMeier estimates of bleeding event-free rate during the first 7 days between control group and Tirofiban group. PCI: percutaneous
coronary intervention, CI: confidence interval (95%).
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impact on long-term outcomes.12 More interesting that
recent study reported the efficacy of even intracoronary
high-dose bolus-only strategy was similar as a standard
high dose intravenous bolus plus infusion strategy.13
There was no thrombocytopenia in the GP IIb/IIIa-
treated group and control group in this study. Likely,
this result was driven by a reversible antagonist of
fibrinogen binding to the GP IIb/IIIa receptor and
short-term administration of Tirofiban.14 Tirofiban, a
non-peptide molecule, is a reversible antagonist offibrinogen binding to the GP IIb/IIIa receptor, the
major platelet surface receptor involved in platelet
aggregation. Platelet aggregation inhibition is revers-
ible following cessation of the infusion of Tirofiban.
Tirofiban has been demonstrated benefit in optimizing
the clinical outcome of STEMI patients undergoing
primary PCI.14,15 Our results suggests that not only
clinical outcomes were compared between control
group and study group but analyzed the effectiveness
and adverse effect in different duration of Tirofiban
groups.
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controlled trials demonstrated that IC administration
of GP inhibitors can yield superior clinical outcomes
compared to IV administration in short-term
(1 monthe3 months) in STEMI patients undergoing
primary PCI. No significant difference was observed
in the frequency of short-term hemorrhage events
with IC administration or IV administration.16 A
similar study with our study including a total of 453
eligible STEMI patients had shown that an additional
intracoronary Tirofiban bolus administration
following upstream intravenous treatment reduced
coronary circulatory platelet activation and inflam-
matory process, and significantly improved myocar-
dial reperfusion and left ventricular function as well
as 6-month major adverse cardiac events-free survival
for STEMI patients undergoing primary PCI.17 Our
randomized clinical pilot demonstrated that in pa-
tients with STEMI undergoing primary PCI, IV
administration with an additional IC bolus adminis-
tration of Tirofiban did not significantly improve
cardiac function at 1 month of PCI compared with
control group. However, coronary angiography after
PCI had shown that the number of TMP grade 3 was
more in Tirofiban group than control group. There was
no significant difference in TIMI flow and TMP grade
among Tirofiban 3 sub-groups.
In our study, STR was higher in the intracoronary
than in the intravenous group (70%e72% vs. 51.95%).
This result is similar to the results by TMP. STR and
TMP represent different pathophysiological phenom-
ena. TMP reflects mechanical patency of the micro-
vasculature, whereas STR may reflect the functional
status of the myocardial cells.18,19 Both markers are
widely accepted as surrogate end points of clinical
outcome and independent prognostic value in predict-
ing long-term mortality. The two markers are assessed
at different time points after primary PCI: TMP
directly after PCI and STR at 30e60 minutes after PCI.
The beneficial effect of intracoronary administration
on myocardial reperfusion may be present directly
after PCI.
GP inhibitors such as abciximab, eptifibatide, and
Tirofiban has been shown to exhibit dose-dependent
activity to dissolve platelet aggregates20 and higher
levels of platelet receptor occupancy was associated
with improved myocardial perfusion among patients
with ST-elevation myocardial infarction.21 Aside from
GP inhibitor-dependent improved disaggregation of
newly formed platelet aggregates, some experimental
studies shown that GP inhibitors (GPIs) exert addi-
tional antiplatelet, antithrombotic, and anti-inflammatory effects when local drug concentrations
are higher.22 These reports eventually gave rise to the
logical hypothesis of choosing the intracoronary route
for GP inhibitors aiming increased local concentrations
with higher levels of platelet GP inhibitor receptor
occupancy leading to more rapid dissolution of
thrombus with improved disaggregation of newly
formed platelet aggregates, which might be eventually
associated with improved myocardial perfusion.23e25
Although our results shown that short time-duration
of IV administration with an additional IC bolus
administration of Tirofiban significantly improves
clinical outcome at 6 month of PCI and does not in-
crease the hemorrhage events compared with control
group in patients with STEMI underwent primary PCI,
this study was a pilot study with a relatively small
sample size, and the follow-up was limited to 180 days.
Longer time research and more patients will be needed
to further demonstrate the above results.References
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